Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Friday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price objective on the medical research company’s stock.

A number of other equities research analysts also recently commented on the company. StockNews.com started coverage on Cytosorbents in a research report on Saturday, December 28th. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.94 on Friday. The firm has a market cap of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The firm has a fifty day moving average price of $0.92 and a 200 day moving average price of $1.02. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Institutional Investors Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents during the 3rd quarter valued at approximately $51,000. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.